Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Greenwich LifeSciences (GLSI) EPS (Weighted Average and Diluted) (2022 - 2025)

Greenwich LifeSciences filings provide 4 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.3 for Q3 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 50.0% to -$0.3 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.46 through Sep 2025, down 82.5% year-over-year, with the annual reading at -$1.21 for FY2024, 75.36% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.3 in Q3 2025 for Greenwich LifeSciences, roughly flat from -$0.3 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.06 in Q2 2022 and bottomed at -$0.61 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.23, with a median of -$0.2 recorded in 2024.
  • The largest annual shift saw EPS (Weighted Average and Diluted) grew 4.55% in 2023 before it plummeted 190.48% in 2024.
  • Greenwich LifeSciences' EPS (Weighted Average and Diluted) stood at -$0.22 in 2022, then increased by 4.55% to -$0.21 in 2023, then plummeted by 190.48% to -$0.61 in 2024, then soared by 50.82% to -$0.3 in 2025.
  • Per Business Quant, the three most recent readings for GLSI's EPS (Weighted Average and Diluted) are -$0.3 (Q3 2025), -$0.3 (Q2 2025), and -$0.25 (Q1 2025).